Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
18.25
-0.23 (-1.24%)
Aug 18, 2026, 9:30 AM EDT - Market open

Trevi Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-59.56-49.33-51.52-33.92-29.91-32.48
Net Income
-51.11-42.76-47.91-29.07-29.15-33.94
Earnings Per Share
-0.35-0.32-0.47-0.29-0.45-1.49
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
318.87188.26107.6282.97120.5136.83
Total Debt
0.610.751.031.349.1814.74
Net Cash (Debt)
318.27187.51106.5981.63111.3322.09
Net Cash Growth
56.78%75.91%30.57%-26.68%404.06%-28.27%
Net Cash Per Share
2.191.391.050.821.720.97

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-52.63-42.09-38.26-31.71-28.18-28.95
Capital Expenditures
-0.24-0.01-0.04-0.14-0.16-
Free Cash Flow
-52.87-42.1-38.29-31.85-28.33-28.95
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.